The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Nebraska Medical Center (UNMC) to assess strategies for targeting transcriptional co-activators in colorectal cancer. The $439,367 award will fund a 5-year research project focused on understanding how the transcriptional coactivator PGC-1B promotes the survival of colorectal cancer cells, particularly in tumors with K-RAS mutations. The project aims to identify...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program will fund a 2-year, $142,295 research project conducted by the Harvard T.H. Chan School of Public Health. The project aims to identify gut microbial and metabolomic biomarkers associated with ultra-processed food (UPF) consumption and their relationship to colorectal cancer (CRC) risk. It will also evaluate the feasibility and initial efficacy of a 6-week medically...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award to the Icahn School of Medicine at Mount Sinai in the amount of $560,297 will fund a 5-year research project to functionally characterize "oncofetal stem cells" in colorectal cancer (CRC). The project aims to: Generate reporters to track the dynamics of CRC stem cell populations, including oncofetal stem cells and LGR5+ cancer stem cells. The researchers will then use these reporters coupled to a...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms of developmental reprogramming in colorectal cancer (CRC). The key objectives are to identify regulators of fetal gene reactivation in CRC cells, determine if the transcription factor SOX9 directly controls fetal gene expression, and evaluate the...
This $205,700 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at addressing the problem of rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance, and to test a novel combination therapy approach of DNA repair inhibition and targeted therapy to prevent resistance...
This $235,620 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Albert Einstein College of Medicine focused on developing a novel therapeutic approach for preventing and treating inflammation-associated colorectal cancer. The key products and services to be delivered under this grant include: Determining the efficacy of the transition state inhibitor MTDIA and related prodrugs for preventing and/or treating...
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...
The National Cancer Institute awarded a $406,611 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives of this 5-year research project are to: 1) characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids, 2) develop and evaluate highly...
This $688,092 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Yale University to investigate the role and regulation of the amino acid asparagine (ASN) in colorectal cancer (CRC) growth and prognosis. The key objectives are to: Determine if the CRC biomarkers ASNS and GPER1 act as sex-specific prognostic indicators in advanced CRC, and assess how CRC treatment impacts ASN-metabolizing gut microbiota. Evaluate how GPER1 and...
This $2,136,715 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is funding a 4-year research project focused on "Harnessing DNA Methylation in Peripheral Blood for Improved Colorectal Cancer Prevention." The primary awardee is the President and Fellows of Harvard College, specifically the Harvard T.H. Chan School of Public Health. Key sub-awards were provided to the Dana-Farber Cancer Institute,...
The National Cancer Institute (NCI), through its Cancer Research Manpower (CFDA 93.398) Federal Grant Program, awarded a $108,706 Project Grant to The Trustees of the University of Pennsylvania (UPenn) to investigate the role of diet and the enzyme ACSS2 in regulating metabolism and epigenetics in colorectal cancer (CRC). The 2-year project aims to determine how the dietary compounds fructose and acetate (from fiber) interact to influence CRC growth and acetyl-CoA metabolism, as well as identify the mechanisms by which these dietary factors and ACSS2 regulate CRC epigenetic modifications and differentiation status. The research will leverage in vitro organoid/cell culture models and in vivo genetic mouse models to provide novel insights into the combinatorial effects of fiber and fructose, and the influence of gene-diet interactions on susceptibility to dietary impacts on CRC. This work has significant implications for developing dietary interventions that can impact cancer patient care.